Are you Dr. Ferrajoli?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 47 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Alessandra Ferrajoli, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1995 - 1998
- University of Perugia Faculty of MedicineClass of 1988
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2000 - 2024
- OK State Medical License 2020 - 2021
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders Start of enrollment: 2002 Oct 01
- Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2002 Oct 01
- FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2006 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study.Che Young Lee, Max J Gordon, Melissa M Markofski, Emily C LaVoy, Susan K Peterson, Liang Li, Sara Fares, Miranda Baum, Margaret Pace, Danielle Walsh, Alessandra Ferraj...> ;Journal of Cancer Survivorship. 2024 Mar 13
- Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.Kang, D., Wang, L., Zhou, S., Shen, C., Short, N., Ferrajoli, A., Wang, Y.> ;Pharmacoeconomics. 2024 Apr 1
- Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.Brown, J., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O'Brien, S., Tam, C., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A...> ;Future Oncology. 2023 Dec 13
- Join now to see all
Authored Content
- L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-Induced HyperbilirubinemiaFebruary 2018
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Press Mentions
- Exploring the CLL/Lymphoma Microenvironment to Improve TherapiesOctober 11th, 2019
- Cancer Patients with Rare Deadly Brain Infection Treated Successfully with Off-the-Shelf Adoptive T-cell Therapy in Clinical TrialOctober 11th, 2018
- [ Inglés] How Does CLL Affect Sinuses and the Skin?September 27th, 2018
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas